Analysts at Stifel Nicolaus initiated coverage on Johnson &
) on Tuesday.
Stifel Nicolaus noted, "We are initiating coverage of Johnson
& Johnson (
) with a Hold rating. We see JNJ as a core health care holding and
total return vehicle in any environment for investors looking for
safety and stability, particularly in these uncertain times. As JNJ
continues to resolve recent issues and ex-FX sales growth
reaccelerates modestly in each year over the next few years, JNJ
shares should sustain its 12.6x forward P/E multiple, in line with
the S&P 500."
Johnson & Johnson shares were down 24 cents, or -0.34%, in
premarket trading on Wednesday.
The Bottom Line
We have been recommending shares of Johnson & Johnson (
) since Apr.27, when the stock was trading at $64.75. The company
has a 3.50% dividend yield, based on last night's closing stock
price of $69.67.
Johnson & Johnson (
) is recommended at this time, holding a Dividend.com DARS™
Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the
Best Dividend Stocks
, as well as a detailed explanation of
our ratings system here
Created by Dividend.com